DEVELOPMENT AND EVALUATION OF DOXORUBICIN ANCHORED PLGA NANOPARTICLES AGAINST BREAST CANCER

Abstract

The objective of this work was to design and develop Poly (D, L-Lactide-co-glycolide) (PLGA) nanoparticles (NPs) of Doxorubicin for the effective treatment of breast cancer. The nanoparticles (NPs) were optimized by applying a Box-Behnken design (BBD) using Design-Expert® Software and prepared using the double emulsification and precipitation method. Three independent factors such as PLGA 50:50 (A), PVA (B), stirring speed (C) were considered. Three dependent responses included entrapment efficiency (Response 1), particle size (Response 2) and Doxorubicin release at 10th hour (Response 3). ATR and DSC studies indicated compatibility between the drug and polymer. The morphological studies performed by SEM showed uniform and spherical shaped discrete particles with smooth surface and in a size range of 282.6 nm. X-ray diffraction was performed to confirm the crystalline nature of the drug after encapsulation. The NPs exhibited a zeta potential of 21.6 mV. In vitro release studies showed a drug release up to 10 hrs. The release kinetics study indicated first order kinetics while the release mechanism followed Higuchi model. The cell viability was found to be more than 80% after incubation with the DOX NPs for 24 h up to a concentration of 80 μg/ml. The DOX NPs treated MCF-7 displayed intrinsic cell damage and cell shrinkage as compared to the control group. It may be concluded from the present investigation that PLGA NPs bearing doxorubicin can effectively treat the breast cancer